Cardinal Health (NYSE:CAH) Stock Gets Price Target Bump from Royal Bank Of Canada

Posted by Brian Himes on Nov 6th, 2026

Cardinal Health (NYSE:CAH – Get Free Report) had its target price boosted by analysts at Royal Bank Of Canada from $276.00 to $295.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Royal Bank Of Canada‘s price objective suggests a potential upside of 8.57% from the stock’s current price.

A number of other analysts have also recently weighed in on CAH. Weiss Ratings upgraded Cardinal Health from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. Mizuho set a $290.00 price objective on Cardinal Health in a report on Thursday. Leerink Partners set a $292.00 price objective on shares of Cardinal Health in a report on Tuesday, August 11th. Evercore reaffirmed an “outperform” rating and issued a $270.00 price target on shares of Cardinal Health in a research note on Wednesday, August 12th. Finally, TD Cowen increased their price target on Cardinal Health from $275.00 to $280.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cardinal Health currently has an average rating of “Moderate Buy” and a consensus price target of $272.50.

View Our Latest Stock Report on CAH

Cardinal Health Trading Up 1.5%

CAH stock traded up $3.88 during midday trading on Friday, reaching $271.70. The company had a trading volume of 626,651 shares, compared to its average volume of 1,953,749. The company has a market capitalization of $62.92 billion, a P/E ratio of 37.59, a PEG ratio of 1.57 and a beta of 0.53. Cardinal Health has a 1 year low of $180.45 and a 1 year high of $286.29. The company has a 50 day moving average of $239.73 and a two-hundred day moving average of $223.24.

Cardinal Health (NYSE:CAH – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $3.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.94 by $0.32. The company had revenue of $67.51 billion during the quarter, compared to the consensus estimate of $66.67 billion. Cardinal Health had a negative return on equity of 98.53% and a net margin of 0.67%. The firm’s revenue was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.55 EPS. On average, sell-side analysts anticipate that Cardinal Health will post 12.55 earnings per share for the current year.

Insiders Place Their Bets

In other Cardinal Health news, insider Michelle D. Greene sold 11,650 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $235.72, for a total transaction of $2,746,138.00. Following the transaction, the insider owned 10,330 shares in the company, valued at approximately $2,434,987.60. This represents a 53.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Jessica L. Mayer sold 29,436 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $236.19, for a total value of $6,952,488.84. Following the sale, the insider owned 33,076 shares of the company’s stock, valued at $7,812,220.44. This trade represents a 47.09% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 210,271 shares of company stock worth $49,626,657 over the last quarter. 0.12% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Allworth Financial LP boosted its position in Cardinal Health by 13.1% during the third quarter. Allworth Financial LP now owns 5,214 shares of the company’s stock worth $1,239,000 after purchasing an additional 603 shares during the period. Fisher Asset Management LLC raised its position in shares of Cardinal Health by 64.8% in the third quarter. Fisher Asset Management LLC now owns 33,955 shares of the company’s stock worth $7,555,000 after buying an additional 13,345 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Cardinal Health by 18.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 558,898 shares of the company’s stock valued at $124,384,000 after acquiring an additional 88,192 shares during the last quarter. Eurizon Capital SGR S.p.A. lifted its position in Cardinal Health by 10.8% during the third quarter. Eurizon Capital SGR S.p.A. now owns 70,583 shares of the company’s stock valued at $15,693,000 after purchasing an additional 6,870 shares during the last quarter. Finally, CENTRAL TRUST Co grew its position in Cardinal Health by 63.0% in the third quarter. CENTRAL TRUST Co now owns 2,135 shares of the company’s stock worth $475,000 after acquiring an additional 825 shares in the last quarter. 87.17% of the stock is owned by institutional investors.

Cardinal Health News Roundup

Here are the key news stories impacting Cardinal Health this week:

Positive Sentiment: Adjusted EPS was $3.26, ahead of analyst expectations of about $2.94, while revenue rose 5% year over year to $67.5 billion and also beat forecasts. Read More.
Positive Sentiment: Cardinal raised its fiscal 2027 adjusted EPS outlook to $12.80–$13.00, above the FactSet estimate of $12.57. Management cited specialty growth, strong generics demand and customer renewals as support for the outlook. Read More.
Positive Sentiment: The company completed a $500 million share-repurchase program during the quarter, adding a capital-return tailwind. Read More.
Neutral Sentiment: Medical distribution faced modest commodity and petroleum-related cost pressure. Strong pharmaceutical sales helped offset the headwinds, but they remain a factor for investors to monitor. Read More.

About Cardinal Health

(Get Free Report)

Cardinal Health, Inc is a healthcare services and products company that supports the distribution and delivery of pharmaceuticals, medical products and related services. The company serves hospitals, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and other healthcare providers.

Its Pharmaceutical and Specialty Solutions segment distributes branded, generic and specialty pharmaceuticals, as well as consumer health products, to pharmacies and healthcare institutions.